Obvious mRNA and protein expression but absence of mutations of the RET proto-oncogene in parathyroid tumors

European Journal of Endocrinology

Volumn 134, Issue 3, 1996, Pages 314-319

  Kimura, Takehiko ^a   Yoshimoto, Katsuhiko ^a   Tanaka, Chisato ^a   Ohkura, Toshihiro ^a   Iwahana, Hiroyuki ^a   Miyauchi, Akira ^b   Sano, Toshiaki ^a   Itakura, Mitsuo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; MOLECULAR BIOLOGY; MUTATION; ONCOGENE; PARATHYROID TUMOR; PRIORITY JOURNAL;

EID: 0029969213     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1340314     Document Type: Article

References (26)

1. Raue F, Frank-Raue K, Grauer A. Multiple endocrine neoplasia type 2. Endocrinol Metab Clin North Am 1994;23:137-56
2. Mulligan LM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, et al. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-60
3. Hofstra RMW, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994;367:375-6
4. Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, et al. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995;10:509-13
5. Blaugrund JE, Johns MM, Eby YJ, Ball DW, Baylin SB, Hruban RH, et al. RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer. Hum Mol Genet 1994;3:1895-7
6. Yoshimoto K, Tanaka C, Hamaguchi S, Kimura T, Iwahana H, Miyauchi A, et al. Tumor specific mutations in the tyrosine kinase domain of the RET proto-oncogene in pheochromocytomas of sporadic type. Endocr J 1995;42:265-70
7. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-65
8. Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue S, et al. Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes, Chromosomes Cancer 1995;12:209-12
9. Santro M, Rosati R, Grieco M, Berlingieri MT, D'Amato GLC, de Fransisis V, et al. The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene 1990;5:1595-8
10. Pachnis V, Mankoo B, Costantini F. Expression of the ret protooncogene during mouse embryogenesis. Development 1993;119: 1005-17
11. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9
12. Takahashi M, Asai N, Iwashita T, Isomura T, Miyazaki K, Matsuyama M. Characterization of the ret proto-oncogene products expressed in mouse L cells. Oncogene 1993;8:2925-9
13. Santro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995;267:381-3
14. Yoshimoto K, Iwahana H, Fukuda A, Sano T, Saito S, Itakura M. Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Cancer Res 1992;52:5061-4
15. Friedman E, Sakaguchi K, Bale AE, Falchetti A, Streeten E, Zimering M, et al. Clonality of parathyroid tumors in familial multiple endocrine neoplasia type 1. N Engl J Med 1989; 321:213-8
16. Cryns V, Yi SM, Tahara E, Gaz RD, Arnold A. Frequent loss of chromosome arm 1p in parathyroid adenomas. Genes, Chromosomes Cancer 1995;13:9-17
17. Arnold A. Molecular mechanisms of parathyroid neoplasia. Endocrinol Metab Clin North Am 1994;23:93-107
18. Cryns V, Thor A, Xu H-J, Hu S-E, Wirman ME, Vickerry Jr AL, et al. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med 1994;330:757-61
19. Yoshimoto K, Iwahana H, Fukuda A, Sano T, Katsuragi K, Kinoshita M, et al. ras Mutations in endocrine tumors: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Jpn J Cancer Res 1992;83:1057-62
20. Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 1995;15:1613-9
21. Tsuzuki T, Takahashi M, Asai N, Iwashita T, Matsuyama M. Spatial and emporal expression of the ret proto-oncogene product in embryonic, infant and adult rat tissues. Oncogene 1995;10: 191-8
22. Kimura T, Yoshimoto K, Yokogoshi Y, Saito S. Mutations in the cysteine-rich region of the RET proto-oncogene in patients diagnosed as having sporadic medullary thyroid carcinoma. Endocr J 1995;42:517-25
23. Brandi M-L, Weber G, Svensson A, Falchetti A, Tonelli F, Castello R, et al. Homozygotes for the autosomal dominant neoplasia syndrome MEN 1. Am J Hum Genet 1993;53:1167-72
24. Wassif WS, Moniz CF, Friedman E, Wong S, Weber G, Nordenskjöld M, et al. Familial isolated hyperparathyroidism: a distinct genetic entity with an increased risk of parathyroid cancer. J Clin Endocrinol Metab 1993;77:1485-9
25. Kassem M, Zang X, Brask S, Eriksen EF, Mosekilde L, Kruze TA. Familial isolated primary hyperparathyroidism. Clin Endocrinol 1994;41:415-20
26. Szabò J, Heath B, Hill VM, Jackson CE, Zarbo RJ, Mallette LE, et al. Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. Am J Hum Genet 1995;55:944-50